VIRX - Viracta Therapeutics Inc
IEX Last Trade
0.215
-0.008 -3.674%
Share volume: 291,109
Last Updated: Fri 30 Aug 2024 09:27:27 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.22
-0.01
-3.54%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-24.20%
1 Month
-55.50%
3 Months
-69.05%
6 Months
-76.00%
1 Year
-84.96%
2 Year
-94.52%
Key data
Stock price
$0.22
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.20 - $1.50
52 WEEK CHANGE
-$0.85
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Dayton Misfeldt
Region: US
Website: http://www.sunesis.com/
Employees: 36
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.sunesis.com/
Employees: 36
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus, and will pursue opportunities to address other serious virus-associated disease.
Recent news